FindTrial
Sign In

A Study to Evaluate the Efficacy and Safety of AD-224

A Randomization, Double-blind, Active-controlled, Multicenter, Phase 3 Trial to Evaluate the Efficacy and Safety of AD-224A and AD-224B in Patients With Essential Hypertension

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06291207
Enrollment
254
Registered
2024-03-04
Start date
2024-04-15
Completion date
2025-04-07
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Essential

Brief summary

The purpose of this study is to evaluate the efficacy and safety of AD-224

Detailed description

Condition or disease : Essential Hypertension

Interventions

DRUGAD-224A

PO, Once daily, 8weeks

DRUGAD-224B

PO, Once daily, 8weeks

DRUGAD-224C

PO, Once daily, 8weeks

DRUGPlacebo of AD-224A

PO, Once daily, 8weeks

DRUGPlacebo of AD-224B

PO, Once daily, 8weeks

DRUGPlacebo of AD-224C

PO, Once daily, 8weeks

Sponsors

Addpharma Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Signed informed consent * Patients with Essential Hypertension * Other inclusions applied

Exclusion criteria

* Patient with Secondary Hypertension * Other exclusions applied

Design outcomes

Primary

MeasureTime frameDescription
Change rate of MSSBPBaseline, Week 8Change from baseline in mean sitting systolic blood pressure

Countries

South Korea

Contacts

PRINCIPAL_INVESTIGATORInHo Chae, M.D., Ph.D

Seoul National University Bundang Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 4, 2026